Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis

Trial Profile

Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Acronyms TERI-DYNAMIC
  • Sponsors Sanofi
  • Most Recent Events

    • 17 Sep 2016 Results assessing effects of teriflunomide treatment on the CD4+ T-cell receptor repertoire presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 21 Apr 2016 Results (n=38) presented at the 68th Annual Meeting of the American Academy of Neurology
    • 11 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top